Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1995 1
1996 1
1997 3
1998 3
1999 1
2000 1
2001 1
2002 3
2003 2
2005 2
2006 3
2007 4
2008 1
2009 2
2010 1
2012 3
2013 1
2014 1
2017 1
2018 2
2019 2
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. O'Rourke DM, et al. Among authors: navenot jm. Sci Transl Med. 2017 Jul 19;9(399):eaaa0984. doi: 10.1126/scitranslmed.aaa0984. Sci Transl Med. 2017. PMID: 28724573 Free PMC article. Clinical Trial.
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Abdul Razak AR, Wilky B, Iyengar M, Trivedi T, Winkle EV, Chagin K, Amado R, Binder GK, Basu S. Ramachandran I, et al. Among authors: navenot jm. J Immunother Cancer. 2019 Oct 24;7(1):276. doi: 10.1186/s40425-019-0762-2. J Immunother Cancer. 2019. PMID: 31651363 Free PMC article.
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma.
D'Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, Grupp S, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite L, Amado R, Mackall CL. D'Angelo SP, et al. Among authors: navenot jm. Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11. Cancer Discov. 2018. PMID: 29891538 Free PMC article. Clinical Trial.
Structure-activity relationship study on small peptidic GPR54 agonists.
Tomita K, Niida A, Oishi S, Ohno H, Cluzeau J, Navenot JM, Wang ZX, Peiper SC, Fujii N. Tomita K, et al. Among authors: navenot jm. Bioorg Med Chem. 2006 Nov 15;14(22):7595-603. doi: 10.1016/j.bmc.2006.07.009. Epub 2006 Aug 1. Bioorg Med Chem. 2006. PMID: 16879969
Physical association of GPR54 C-terminal with protein phosphatase 2A.
Evans BJ, Wang Z, Mobley L, Khosravi D, Fujii N, Navenot JM, Peiper SC. Evans BJ, et al. Among authors: navenot jm. Biochem Biophys Res Commun. 2008 Dec 26;377(4):1067-71. doi: 10.1016/j.bbrc.2008.10.108. Epub 2008 Oct 31. Biochem Biophys Res Commun. 2008. PMID: 18977201
43 results